RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive ca

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biophar

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive

NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) toda

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward form

Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a I

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight

Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equa

FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a B

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved fo

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the d

Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ne

Analysts downgraded UiPath, Cal-Maine with several price-target cuts.

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight

JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight

Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and

Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regu

Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial f

U.S. stocks climbed, led by Dow’s 600-point gain; services PMI strengthened, Snowflake surged, while

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lo

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ove

U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and R

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a B

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and

Ultragenyx reports Phase 3 Aspire study of apazunersen failed to meet primary endpoints, prompting p

Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.

Analysts revised price targets for Ultragenyx, UiPath, Netskope, Snowflake, Magnite, Broadcom, Crowd

Evercore ISI Group analyst Liisa Bayko downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Ou

Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market se

U.S. futures rose, but NetApp fell 8.2% after earnings. Ultragenyx plunged 45% on a failed trial; HP

Baird analyst Joel Beatty downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to N

AVGO: -5% | AVGO stock has given up its prior loss. Broadcom shares were trading lower after the com

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ultragenyx Pharmaceutical (NASDAQ:RA

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers an

Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-mar

Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive ra

Ultragenyx reports positive 96-week Phase 3 results for GENGLYCOS in GSDIa patients, showing sustain

Wells Fargo analyst Michael Turrin maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overw

JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Over

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a B

Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ove

Ultragenyx shares rise after FDA approval of Genglycos, with a $2.7 million wholesale cost and $362